← Back to Search

Antimuscarinic Agent

Fesoterodine (Double-Blind) for Overactive Bladder

Phase 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 2, week 6 and week 12
Awards & highlights

Summary

This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.

Eligible Conditions
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 2, week 6 and week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 2, week 6 and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline.
Secondary study objectives
Categorical Change in Patient Perception of Bladder Condition (PPBC) Score Relative to Baseline
Categorical Change in Urgency Perception Scale (UPS) Relative to Baseline
Change in Frequency-urgency Sum Per 24 Hours Relative to Baseline
+9 more

Side effects data

From 2010 Phase 4 trial • 331 Patients • NCT00806494
30%
Dry mouth
9%
Constipation
9%
Diarrhoea
8%
Urinary tract infection
5%
Dyspepsia
5%
Nausea
5%
Headache
3%
Fatigue
3%
Dizziness
2%
Dry eye
2%
Back pain
2%
Cough
2%
Dry throat
1%
Oedema peripheral
1%
Diverticulitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Fesoterodine

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Fesoterodine (Double-Blind)Experimental Treatment1 Intervention
Group II: Placebo (Double-Blind)Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fesoterodine
FDA approved

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,638 Previous Clinical Trials
17,739,230 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,527 Previous Clinical Trials
14,911,363 Total Patients Enrolled
~49 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top